Organon (NYSE: OGN) received FDA acceptance to review a supplemental New Drug Application for its hormone free contraceptive ...
EMPAVELI-treated adolescents achieved a 75% relative reduction in proteinuria within 6 months versus placebo EMPAVELI is the only approved ...
EMPAVELI-treated adolescents achieved a 75% relative reduction in proteinuria within 6 months versus placebo ; EMPAVELI is the only approved treatment for adolescents with C3G and ...
This week, a Senate committee scheduled a hearing for President Trump’s nominee to lead FDA, new reporting sheds light on the ...
Biogen published results from a prespecified adolescent subgroup analysis of the Phase 3 VALIANT study evaluating EMPAVELI (pegcetacoplan) in the Clinical Journal of the American Society of Nephrology ...
Morgan Stanley 24th Annual Global Healthcare Conference September 16, 2026 11:30 AM EDTCompany ParticipantsKabir Nath - ...
A federal appeals court is weighing another challenge to mifepristone, the medication used in most abortions in the United ...
EMPAVELI significantly reduced proteinuria in adolescents with kidney diseases, following an FDA label expansion for this age group. Biogen has announced that adolescents treated with EMPAVELI® ...
Designed for busy practitioners, the in-person symposium offers a concise but comprehensive look at the latest research, ...
Compass Pathways (NASDAQ:CMPS) said it expects to complete its rolling New Drug Application submission for its synthetic ...
Ahead of the midterm elections, the president said that all states had opted in to an effort to align Medicaid’s prices for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results